Literature DB >> 8971157

Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.

K Yanagisawa1, M Kondo, H Osada, K Uchida, K Takagi, A Masuda, T Takahashi, T Takahashi.   

Abstract

Chromosome 3p is frequently deleted in various cancers including examples in the lung. A novel gene, termed FHIT, was recently isolated from the fragile site at 3p14.2, with aberrant transcripts being reported in lung cancer tumor specimens. To avoid overlooking tumor-specific altered transcripts due to contaminating normal cells in primary tumors, FHIT alterations were examined in 41 lung cancer cell lines in the present study. Lack of detectable expression or exclusive expression of aberrantly spliced transcripts, often accompanied by intragenic homozygous deletions, were observed in 7 of 24 non-small cell lung cancers (29%) but in 0 of 17 small cell lung cancers (0%). Extensive reverse transcription-PCR-single-strand conformation polymorphism analysis revealed polymorphisms and alternative splicing but failed to identify point mutations. These results suggest distinct mechanisms for FHIT alterations in lung tumorigenesis and that further studies of this interesting gene are warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971157

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population.

Authors:  Hae-Yun Jung; Jae Sook Sung; Young Mi Whang; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Hwa Jung Sung; In Keun Choi; Sang Cheul Oh; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2007-07-04       Impact factor: 3.172

2.  FHIT gene expression is repressed by mitogenic signaling through the PI3K/AKT/FOXO pathway.

Authors:  Kevin Kelley; Steven J Berberich
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

3.  Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins.

Authors:  C Brenner; P Garrison; J Gilmour; D Peisach; D Ringe; G A Petsko; J M Lowenstein
Journal:  Nat Struct Biol       Date:  1997-03

4.  Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation.

Authors:  Z Guo; J K Vishwanatha
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

5.  Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

Authors:  R Baffa; L G Gomella; A Vecchione; P Bassi; K Mimori; J Sedor; C M Calviello; M Gardiman; C Minimo; S E Strup; P A McCue; A J Kovatich; F Pagano; K Huebner; C M Croce
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein.

Authors:  C Brenner; H C Pace; P N Garrison; A K Robinson; A Rosler; X H Liu; G M Blackburn; C M Croce; K Huebner; L D Barnes
Journal:  Protein Eng       Date:  1997-12

7.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

8.  Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells.

Authors:  M Carapeti; R C Aguiar; H Sill; J M Goldman; N C Cross
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

9.  Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers.

Authors:  Y-C Lee; C-T Wu; J-Y Shih; Y-S Jou; Y-L Chang
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

10.  Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers.

Authors:  Y-L Chang; C-T Wu; J-Y Shih; Y-C Lee
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.